Company intelligence / Profile preview

BioAlliance Pharma

Ownership: Private
Development stage: Other

Overview

Livatag® showed a significant survival increase (~17 months additional survival vs. control group) in advanced hepatocellular carcinoma patients during phase II trials, leading to a phase III trial initiation. Loramyc®/Oravig®, targeting oropharyngeal candidiasis, was registered/commercialized in multiple countries. Sitavig®, based on acyclovir Lauriad®, was registered for herpes labialis. AMEP biotherapy showed promising preliminary results in metastatic melanoma.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeNanoparticleBiologic
Industry: Biotech

Drug pipeline

3 assets

Loramyc

Unknown

2 more assets in the full pipeline.

Request access →

Partnerships

Vestiq Pharmaceutical (US commercialization partner for Oravig)Sosei and Fujifilm Pharma (Japan development/commercialization partners)

Beyond the preview

Go deeper on BioAlliance Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioAlliance Pharma.

Explore the full profile